| abstract |
Pharmaceutical compositions of hepatitis C virus protease inhibitors and methods of using these compositions to inhibit hepatitis C virus (HCV) replication and to treat HCV infection are disclosed. These compositions are lipid-based and contain hepatitis C virus protease inhibitors at least one pharmaceutically acceptable amine, at least one pharmaceutically acceptable base, at least one pharmaceutically acceptable. Contains with acceptable oils and optionally one or more additional ingredients. |